Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2010

View Archived Issues

Medvir discovers novel selective cathepsin K inhibitors

Boehringer Ingelheim claims new inhibitors of microsomal prostaglandin E synthase 1

Italian scientists claim new agents with antimalarial activity

NeuroSearch discloses new potassium channel modulators

Gilead discloses clinical data on HCV NS3 protease inhibitor GS-9256

Characterization of filibuvir resistance in HCV patients when coadministered with PEG-INF/RBV

Dual PI3K-alpha/mTOR inhibitors discovered by Pfizer

Preclinical and phase I data presented on antimicrobial pleuromutilin BC-3781

Cheminpharma presents preclinical data on new MEK 1 inhibitor

Pfizer describes new oxazolidinone antibacterial

Hospira enters definitive merger agreement to acquire Javelin

EMA recommends Cell Therapeutics submit revised PIP for pixantrone

Swedish Orphan Biovitrum's Kiobrina improves preterm infant growth speed in phase II trial

Novel photosensitizer porphyrins discovered at CeramOptec

Silence Therapeutics and AstraZeneca extend siRNA delivery collaboration

FDA approves Stemedica's IND to evaluate stem cells in ischemic stroke patients

Dutogliptin reduces HbA1c in phase III trial in type 2 diabetes

Alexion reaches enrollment goals in Solaris trials in atypical hemolytic uremic syndrome

EMA's COMP notifies CytRX of positive opinion on bafetinib in CML

NeoPharm starts enrollment in phase II LE-DT trial in pancreatic cancer

Genentech and Seattle Genetics to renew antibody-drug conjugate collaboration

DBM receives NIH grant to continue developing anti-inflammatory phytochemicals

NanoBio and University of Michigan launch program for therapeutic intranasal HBV vaccine

FDA approves Zortress to prevent kidney transplant rejection in adults

Biotie maintains global rights to BTT-1023 for inflammatory diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...